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On 17 June of 2020, 
we held the first 
COVID-19 health 
preference research 
roundtable as 
an open meeting 
of the minds, 
allowing a healthy 
exchange of ideas 
between these 
study teams and 
other attendees 
interested in the 
area.
Like the rest of the world, the pandemic has reshaped the lives and livelihoods 
of scientists in the health economics 
and outcomes research community. 
Many investigators in health preference 
research reacted by conducting empirical 
studies to better understand the value 
of health and health-related alternatives 
affected by COVID-19. To the best of 
our knowledge, we identified 18 health 
preference studies currently under review 
or ongoing. On 17 June of 2020, we held 
the first COVID-19 health preference 
research roundtable as an open meeting 
of the minds, allowing a healthy exchange 
of ideas between these study teams and 
other attendees interested in the area. 
From that discussion, this summary 
characterizes the state of our science for 
the broader scientific community and for 
regulators and other decision makers 
looking for preference evidence regarding 
COVID-19.
As defined by the International Academy 
of Health Preference Research, a health 
preference study uses observational and 
experimental methods to collect empirical 
evidence on health-related choices. The 
18 studies discussed here focused on 
stated preferences, specifically testing the 
causal relationships between attributes 
and preferential choice behaviors related 
to COVID-19. Due to their preliminary 
nature, the studies are not cited directly 
here; instead, this summary will attempt 
to describe initial experiences of the 
health preference research community, 
not the findings of individual studies.
Given that COVID-19 is a new topic 
in health preference research, it was 
remarkable to hear about so many 
independent studies from Australia, 
Canada, China, France, Germany, New 
Zealand, The Netherlands, the United 
Kingdom, and the United States. Most 
sought to study preferences of the 
general population on alternative policies 
and the tradeoffs involved, either in a 
single country or in multiple countries. 
Others focused on individual health 
interventions, attempting to predict 
uptake of COVID-19 vaccines and of 
contact-tracing apps. Many topics 
remain untouched, such as clinical trial 
participation, labor decisions, testing, and 
long-term care. COVID-19 has affected 
nearly all aspects of our daily lives and 
COVID-19 health preference research will 
likely expand immensely over the coming 
months with little risk of duplication. This 
article emphasizes the lessons learned 
that are particularly relevant when 
conducting a COVID-19 health preference 
research study.
First Lesson Learned
The first lesson is that public perspectives 
regarding COVID-19 are evolving. In 
practical terms, starting and finishing 
a study quickly (ie, within 30 days) may 
be exciting and expeditious, but in 
retrospect, early evidence may age more 
quickly. A once perfectly valid instrument 
may be out of date 2 weeks later when 
preparing the results for dissemination. 
Although these rapid-cycle studies could 
provide near real-time information 
for policy decisions, traditional peer 
review timelines limit their potential. 
Nevertheless, publication of these studies 
can provide important snapshots of the 
public’s perspectives and can inform the 
design of sequential studies. Study teams 
may be wise to consider pairing their 
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study objectives with dissemination plans to avoid the potential 
obsolescence of preference evidence due to changes in the 
context or as respondents gain greater firsthand experience 
with COVID-19.
Second Lesson Learned
The second lesson is that nearly all epidemiologic interventions 
and their social impacts are legitimately complex, which makes 
them challenging to convey to the general population in a health 
preference study. Furthermore, trading off among attributes 
often presents a moral dilemma, calling for the interpretation of 
a philosopher as much as an economist. For example, choosing 
to wait for a more effective vaccine may imply time preferences, 
but also has distributional consequences within the population. 
In most countries, the burden of COVID-19 in terms of health 
and employment has been far from uniform.
Third Lesson Learned
The third lesson concerns the inelastic demand for goods and 
services, such as masks, contact tracing apps, and vaccines. 
Some people are nontraders who are implacably in favor of or 
against a good or service (eg, anti-vaxxers), regardless of the 
attributes. Such persons absolutely will or will not comply with 
public health recommendations. Knowing the proportion of 
nontraders is required to accurately predict uptake; however, 
surveying their preferences on alternatives is uninformative. 
Some researchers have argued that stated preference surveys 
are bad at predicting uptake but good at quantifying rates 
of substitution. The ideal approach may be to pool stated 
and revealed preference evidence to identify both rates of 
substitution and predicted uptake. In any case, it is important to 
acknowledge the limits of preference evidence when capturing 
the factors that drive real-world behaviors (eg, working to 
support a household).
Some characteristics of nontraders make health preference 
researchers feel uneasy. Nontraders can have nuanced 
reasoning or be willfully ignorant. Others have distinct political 
views that are well outside the mainstream. Each country has 
its own aberrant subpopulations. Such eccentric views on the 
burden of disease or the risks may be scientifically valid or 
unfounded, but, if a preference study attempts to change them, 
the study will fail to predict real-world behavior. For example, 
completing forced choice tasks on vaccinations (without an opt-
out) may train persons to choose vaccination when given an opt-
out. By altering respondents’ perspectives, study teams switch 
from positive economics (ie, describing what is) to normative 
economics (what should be).
Fourth and Final Lesson
The last lesson is to recognize that the world is at the start of a 
pandemic like no other in terms of infectious spread and media 
attention. Understanding what drives uptake and other health-
related behaviors is critically important for nearly every country. 
Capturing preference evidence now on tradeoffs and priorities 
can provide an evidentiary basis for health system reforms in the 
near and long-term. Some researchers are using this moment to 
develop innovative prioritization tools (eg, ventilator allocation) 
that may have applications across multiple future areas. Even 
when we overcome this challenge, there will likely be another 
“someday” with similar traits. 
The attendees of the first roundtable expressed unanimous 
support for COVID-19 health preference research and hoped 
to see these and many more studies published in the coming 
months to inform regulatory decisions, economic evaluations, 
clinical practice, and health policy. •
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